EM 523

structure given in first source

Also Known As:

EM-523; EM523L; N-ethyl-N-demethyl-8,9-anhydroerythromycin A 6,9-hemiketal; de-(N-methyl)-N-ethyl-8,9-anhydroerythromycin A 6,9-hemiacetal; Erythromycin, 8,9-didehydro-9-deoxo-6-deoxy-6,9-epoxy-

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - Polyketides: 231
    - Macrolides: 4391
      - Erythromycin: 3910
        EM 523: 4

Related Diseases

1.	Gastroparesis 11/01/1994 - "In this pilot study, EM523L was administered to six patients with diabetic gastroparesis, and its effects on gastric emptying function and the change in plasma glucose levels after eating were examined. " 11/01/1994 - "From these results, we concluded that intravenous administration of EM523L in patients with severe diabetic gastroparesis promotes gastric emptying of a solid and liquid meal and, as a result, plasma glucose levels increase after eating." 11/01/1994 - "Effect of intravenous administration of EM523L on gastric emptying and plasma glucose levels after a meal in patients with diabetic gastroparesis: a pilot study." 07/01/1997 - "To evaluate the effect of the erythromycin derivative EM523L on gastric emptying and postprandial insulin requirement in insulin-dependent diabetic patients with severe gastroparesis. " 11/01/1989 - "These results indicate that EM-523 mimics motilin in stimulating gastrointestinal motility and that this agent may be useful treat gastrointestinal disorders such as gastric stasis, gastroesophageal reflux, and postoperative ileus, and so forth."
2.	Ileus 09/01/1991 - "Furthermore, we have investigated the effects of EM-523 both in postoperative ileus dogs and truncally vagotomized dogs. " 09/01/1991 - "These results indicated that EM-523 may be useful as a gastroprokinetic drug for postoperative ileus and the patients with vagotomy." 11/01/1989 - "These results indicate that EM-523 mimics motilin in stimulating gastrointestinal motility and that this agent may be useful treat gastrointestinal disorders such as gastric stasis, gastroesophageal reflux, and postoperative ileus, and so forth."
3.	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 11/01/1989 - "These results indicate that EM-523 mimics motilin in stimulating gastrointestinal motility and that this agent may be useful treat gastrointestinal disorders such as gastric stasis, gastroesophageal reflux, and postoperative ileus, and so forth."
4.	Gastroesophageal Reflux (GERD) 11/01/1989 - "These results indicate that EM-523 mimics motilin in stimulating gastrointestinal motility and that this agent may be useful treat gastrointestinal disorders such as gastric stasis, gastroesophageal reflux, and postoperative ileus, and so forth."
5.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/01/1997 - "In six IDDM patients with severe gastroparesis (two men and four women, mean age 44.5 years [range 36-53]), the insulin infusion pattern during feedback control with an artificial endocrine pancreas device (Biostator) after intake of a test meal, the retention rate of residual isotope ([99m]Tc-labelled Sn-colloid) in the stomach, and the time-concentration curve of plasma acetaminophen as the marker for liquid emptying were studied with EM523L or a control placebo Time courses of insulin infusion rates peaked within 120 min after intake of the test meal in the EM523L phase, whereas no apparent peak rates were observed in the control phase. "

Related Drugs and Biologics

1.	Motilin
2.	Isotopes
3.	Insulin (Novolin)
4.	Glucose (Dextrose)
5.	Erythromycin (Erycette)
6.	Colloids (Colloid)
7.	Acetaminophen (Paracetamol)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Vagotomy
3.	Insulin Infusion Systems